Drug Approval | June 01, 2022
FDA approves Roche’s Evrysdi for use in babies under two months with SMA
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
Perrigo expects to launch Omeprazole Minis later this year
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Subscribe To Our Newsletter & Stay Updated
